肝血栓调节蛋白基因沉默降低血小板计数并延缓MMTV-PyMT小鼠乳腺癌进展
研究用反义寡核苷酸沉默肝脏THPO基因,使小鼠和狒狒血浆血栓调节蛋白及血小板计数持续下降约50%。在MMTV-PyMT乳腺癌小鼠中,该治疗延长了至安乐死时间,并降低肿瘤生长、血管化及肺转移,提示在止血安全范围内适度降低血小板可延缓血小板依赖性病理进程。
要点
- THPO-ASO可选择性沉默肝脏THPO,4周内使小鼠和狒狒血小板及血浆血栓调节蛋白降约50%。
- 在MMTV-PyMT小鼠中,THPO-ASO延长至安乐死时间并减少肺转移。
- 治疗还降低血小板因子4、VEGF、骨髓巨核细胞密度及肿瘤血管化。
核心结论
- 持续适度降低血小板计数在止血安全范围内可行,并可延缓某些血小板依赖性病理进程。
研究设计与样本
- 临床前研究:合成小鼠和灵长类特异性THPO-ASO,重复给药于小鼠和一只狒狒。
- 在6周龄转基因MMTV-PyMT小鼠中评估THPO-ASO对肿瘤进展的影响,该模型2至3个月内发生cMPL阴性致命转移性乳腺癌。
主要发现
- THPO-ASO使小鼠和狒狒血浆血栓调节蛋白水平及血小板计数在4周内持续下降50%。
- THPO-ASO治疗增加MMTV-PyMT小鼠至安乐死(主要人道终点,联合可触及肿瘤体积2 cm3)的平均时间。
- 与未治疗对照相比,THPO-ASO降低血小板计数、血浆血小板因子4、VEGF、血栓调节蛋白水平、骨髓巨核细胞密度、肿瘤生长速率、增殖指数、血管化、血小板和巨噬细胞含量及肺转移。
临床怎么用
- THPO-ASO代表一种在止血安全范围内药理学降低血小板计数的可行策略。
- 该策略可能延缓某些血小板依赖性病理过程,但尚未在人体验证。
局限性
- 研究为临床前动物模型,狒狒样本量未报告,人体有效性和安全性未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In humans, platelet count within the normal range is required for physiological hemostasis, but, adversely, platelets also support pathological thrombosis. Moreover, by releasing growth factors, they may enhance neoplastic proliferation. We hypothesize that platelet count correlates with platelet-dependent pathologies, even within the range of hemostatic competence. Because platelet production is promoted by thrombopoietin signaling through the myeloproliferative leukemia virus oncogene (cMPL), a receptor expressed on megakaryocytes, we evaluated the feasibility of selective targeting of hepatic thrombopoietin production to test this hypothesis. We synthesized murine- and primate-specific antisense oligonucleotides (THPO-ASO) that silence hepatic thrombopoietin gene (THPO) expression without blocking extrahepatic THPO. Repeated doses of THPO-ASO were administered to mice and a baboon, causing a sustained 50% decline in plasma thrombopoietin levels and platelet count within 4 weeks in both species. To investigate whether reducing platelet count within the translationally relevant hemostatic range could alter a neoplastic process, we administered THPO-ASO to 6-week-old transgenic MMTV-PyMT mice that develop early ductal atypia that progresses into cMPL-negative fatal metastatic breast cancer within 2 to 3 months. THPO-ASO treatment increased the average time to euthanasia (primary humane endpoint) at 2 cm3 combined palpable tumor volume. Our results show that THPO-ASO reduced blood platelet count, plasma platelet factor 4, vascular endothelial growth factor, thrombopoietin levels, bone marrow megakaryocyte density, tumor growth rate, proliferation index, vascularization, platelet and macrophage content, and pulmonary metastases vs untreated controls. These findings confirm that sustained and moderate pharmacological platelet count reduction is feasible with THPO-ASO administration and can delay progression of certain platelet-dependent pathological processes within a safe hemostatic platelet count range.
引用
- Shirai T, Revenko AS, Tibbitts J, et al. Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice. Blood Adv. 2019. PMID: 31648335. doi:10.1182/bloodadvances.2019000250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。